Business
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen
WEST CHESTER, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), announces with deep sadness the passing of Glenn
About this update from Verrica Pharmaceuticals Inc.
[{"type":"text","content":"WEST CHESTER, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019.\n “Glenn was a renowned figure in the dermatology industry, and he brought a wealth of experience and energy, as he served our team with passion and commitment to advancing not only Verrica’s science and business, but the way in which the Company aimed to address a substantial unmet need, and serve its stakeholders with excellence,” said Paul B. Manning, Chairman, Board of Directors, Verrica Pharmaceuticals. “Glenn was a strategic thinker, with exceptional business acumen, and he partnered with us as a colleague and collaborator. To me, Glenn was not only a critical component of our growth and success; he was a teammate and a friend, and he will be missed.” Mr. Oclassen joined the Verrica Board of Directors in December, 2015. He was formerly the President and Chief Executive Officer, and a director, of Transcept Pharmaceuticals. Prior, he founded Oclassen Pharmaceuticals, which was sold to Watson Laboratories in 1997. About Verrica Pharmaceuticals Inc. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and common warts. Molluscum is a highly contagious viral skin infection affecting approximately six million people, primarily children, in the United States, and common warts are contagious skin growths affecting 22 million people. There are currently no FDA-approved treatments for molluscum or common warts. Following positive topline results from two pivotal Phase 3 trials, the Company submitted an NDA in September 2019 for VP-102 for the treatment of molluscum. Verrica is planning to meet with the FDA to determine next steps on the development of VP-102 for common warts following positive Phase 2 results. VP-102 is also currently in a Phase 2 trial for the treatment of external genital warts. A second product candidate, VP-103, is in pre-clinical development for plantar warts. For more information,...